
    
      The study consisted of a Screening Period of 2 to 4 weeks, a 4-week placebo Baseline Period,
      a 2-week Titration Period, a 12-week Maintenance Period, and a 4-week Follow-up Period.
      During the entire study the subjects had a diary to document the occurrence, duration, and
      intensity of headaches, the occurrence or not of aura and its nature, as well as other
      related symptoms, and the use of study medication and acute medication.
    
  